Search

Displaying results 3451 - 3460 of 8010 in total
  1. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity. … Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects.

  2. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840).

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Phenprocoumon

    go.drugbank.com/drugs/DB00946
    ApprovedInvestigationalWithdrawn

    Coumarin derivative that acts as a long-acting oral anticoagulant.

    Categories: Vitamin K Inhibitors, Vitamin K Antagonists
  4. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Ecallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection. … Apart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].

  5. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  6. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … [A262097] On November 8th, 2023, fruquintinib was approved by the FDA under the brand name Fruzaqla for the treatment of adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine

  7. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway. … and other lipids from cells including those in the arterial wall.

  8. Drug

    MK-0731

    go.drugbank.com/drugs/DB08037
    Investigational

    MK-0731 is a kinesin spindle protein inhibitor and antineoplastic agent.

  9. Drug

    Erythrityl tetranitrate

    go.drugbank.com/drugs/DB01613
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)

  10. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with … [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.